mBeach Software Inc. Finalizes Acquisition of Skin Cancer Scanning Ltd.


TEL AVIV, Israel, July 15, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) announced today that it has finalized and closed the merger for the acquisition of Skin Cancer Scanning Ltd. ("SCS"). As a result of the acquisition, MBHS will hold 100% of SCS.

The former management of MBHS has been entirely replaced by the new management of SCS.

MBHS has filed several 8-k reports with the Securities and Exchange Commission pertaining to the transaction including a super 8-k. We invite the public to review them and obtain more information.

MBHS's new CEO, Mr. Yossi Biderman, Col., stated, "We feel that the merger between MBHS and SCS will greatly increase shareholder value. We believe SCS is a very exciting company with strong potential to succeed in the global market for advanced technologies to better detect skin cancers."

About SCS

Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.

Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.

For more information on SCS, visit www.scs-med.com.

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.



            

Contact Data